Philippe Delataille
Genfit (France)(FR)
Publications by Year
Research Areas
Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Cardiovascular Function and Risk Factors, Peroxisome Proliferator-Activated Receptors, Biochemical effects in animals
Most-Cited Works
- → Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis(2013)404 cited
- → The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma–associated adverse cardiac effects(2014)36 cited
- → RORgt Inhibition in the Liver Prevents Hepatic Fibrosis Progression, a Proof of Concept Study with a Potent, First in Class, Hepatocentric RORgt Inverse Agonist(2016)2 cited
- → Improvement of hepatic and extrahepatic functions and anti-inflammatory effects of nitazoxanide in disease models of LPS-induced systemic inflammation and acute-on-chronic liver failure(2022)1 cited
- → WED-105 Nitazoxanide directly protects from stress-induced cell death to alleviate liver damage in preclinical models of acute-on-chronic liver failure(2024)1 cited
- → #1008 Nitazoxanide alleviates kidney damage and restores renal function in disease models of acute-on-chronic liver failure(2025)
- → Nitazoxanide counteracts lipopolysaccharide-induced hepatic and renal transcriptomic profile changes to improve systemic inflammation and organ damage in a disease model of acute-on-chronic liver failure(2023)
- → THU-166 NTZ alleviates stress-induced hepatocyte cell death through modulation of oxidative stress and DNA damage signaling pathways in ACLF models(2025)